AR and prostate carcinoma: Importantly, AR variants such as AR-v7 and ARv567es arise from intricate AR genomic arrangements and dysregulation of AS factors [63, 64], and have been shown to be constitutively active in CRPC patients and prostate cancer cell models [86–89].